Roger K Verbeeck
Overview
Explore the profile of Roger K Verbeeck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
650
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singu B, Akpabio P, Verbeeck R
Afr Health Sci
. 2023 Mar;
22(3):436-441.
PMID: 36910388
Background: World Health Organization (WHO) advocates use of weight bands in antiretroviral therapy (ART) guidelines. Allometric scaling could be a more reliable method because it uses a non-linear approach in...
2.
Singu B, Morrison H, Irengeya L, Verbeeck R
Afr J Lab Med
. 2022 Aug;
11(1):1628.
PMID: 35937763
Background: Phenytoin and valproic acid, anticonvulsants, have a low therapeutic index and are highly plasma protein bound, mainly to albumin. Hypoalbuminaemia is common in critically ill patients and increases the...
3.
Singu B, Verbeeck R
J Pharm Pharm Sci
. 2021 Jun;
24:329-335.
PMID: 34192509
Codeine continues to be widely used as an analgesic, antidiarrhoeal and antitussive agent. Its analgesic effect depends on its biotransformation to morphine, a strong opioid. The highly variable biotransformation of...
4.
Kibuule D, Aiases P, Ruswa N, Rennie T, Verbeeck R, Godman B, et al.
ERJ Open Res
. 2020 Mar;
6(1).
PMID: 32201689
Background: In Namibia, one out of every 25 cases of tuberculosis (TB) is "lost to follow-up" (LTFU). This has impacted negatively on national efforts to end the disease by 2035....
5.
Verbeeck R, Singu B, Kibuule D
Clin Pharmacokinet
. 2019 Jul;
58(12):1511-1515.
PMID: 31332668
No abstract available.
6.
Kibuule D, Verbeeck R, Nunurai R, Mavhunga F, Ene E, Godman B, et al.
Expert Rev Respir Med
. 2018 Sep;
12(11):979-987.
PMID: 30198358
Objectives: Optimal treatment success rates are critical to end tuberculosis in Namibia. Despite the scale-up of high quality directly observed therapy short-course strategy (DOTS) in Namibia, treatment success falls short...
7.
Singu B, Mubita M, Thikukutu M, Mufenda J, McKenzie S, Verbeeck R
Int J Clin Pharm
. 2018 Mar;
40(3):520-525.
PMID: 29594677
Background Therapeutic drug monitoring is frequently used to optimize the gentamicin dose. Objective The study investigated whether a 240 mg once daily standard dose achieves the recommended target serum gentamicin...
8.
Verbeeck R, Kanfer I, Lobenberg R, Abrahamsson B, Cristofoletti R, Groot D, et al.
J Pharm Sci
. 2017 Apr;
106(8):1933-1943.
PMID: 28435140
Literature data relevant to the decision to allow a waiver of in vivo bioequivalence testing for the marketing authorization of immediate-release, solid oral dosage forms containing enalapril maleate are reviewed....
9.
Alffenaar J, Tiberi S, Verbeeck R, Heysell S, Grobusch M
Clin Infect Dis
. 2016 Oct;
64(1):104-105.
PMID: 27789609
No abstract available.
10.
Verbeeck R, Gunther G, Kibuule D, Hunter C, Rennie T
Eur J Clin Pharmacol
. 2016 Jun;
72(8):905-16.
PMID: 27305904
Introduction: Tuberculosis (TB) remains one of the world's deadliest communicable diseases. Although cure rates of the standard four-drug (rifampicin, isoniazid, pyrazinamide, ethambutol) treatment schedule can be as high as 95-98 ...